Sellas, Life

Sellas Life Sciences: Placement Closes at $172.5 Million as REGAL Data Sit Alongside a Bigger Share Count

Published on 11/22/2026 at 17:11 | Editorial boerse-global.de
Sellas closed its $172.5M placement at $13.00 per share, with shares down 8.1%, as investors weigh dilution against REGAL Phase III survival data.
Sellas Life Sciences Illustration mit AI erstellt.

Sellas Life Sciences wrapped up its public share placement on Friday, and the market's response was swift: the stock closed 8.1% lower as investors weighed the cost of fresh equity against the clinical progress the company has been touting. The offering, priced at $13.00 per share on November 18, ultimately comprised 13,269,231 shares — a figure that includes the full exercise of the underwriters' overallotment option — for gross proceeds of $172.5 million.

That "gross" qualifier matters. Placement discounts, commissions and other offering expenses still come out of the headline number, so the actual cash inflow will land below the stated total. Sellas had originally targeted $150.0 million in gross proceeds; the bankers' 30-day option to buy additional shares, exercised in full, is what pushed the transaction to its final size.

Two Questions, Not One

The placement and the clinical program answer entirely different questions, and conflating them serves neither. A capital raise speaks to the balance sheet; a Phase III readout speaks to the science. Treating a financing decision as a seal of approval for the entire investment case is a shortcut that skips the hard part.

On the balance-sheet side, the picture is straightforward. The raise bolsters Sellas's capital base, but it does so by issuing new stock — meaning existing holders absorb dilution of their stakes. That tension, rather than any single headline, is the more useful frame for assessing where the company stands.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

What the Trial Showed

The medical story centers on REGAL, the Phase III study of galinpepimut-S in acute myeloid leukemia. Sellas reported last week that the trial met its primary endpoint of overall survival. Median overall survival came in at 24.0 months, against 14.7 months for patients on the best available therapy — a 41% reduction in the risk of death, according to the company. The hazard ratio was 0.59, with a p-value of 0.035.

Those numbers are the clinical core of the story. The financing step neither replaces them nor diminishes them. What investors need to hold separately is the strength of the evidence and the status of the regulatory path.

The Filing Is Still Ahead

Sellas said it plans to discuss an accelerated submission strategy with the FDA and is preparing a biologics license application for the first half of 2027. Those remain intentions, not achievements — the endpoint has been met, but the conversations and the application preparations are still to come.

Sellas Life Sciences at a turning point? This analysis reveals what investors need to know now.

The third-quarter figures, released November 12, add another layer. Sellas posted a net loss of $10.1 million for Q3 2026, wider than the $6.8 million shortfall in the same period a year earlier. Cash and cash equivalents stood at $134.7 million at quarter-end.

What Investors Are Left to Weigh

Sellas cannot be reduced to either the share-price slide or the cash infusion. The raise is done; the regulatory path the company has sketched out lies ahead. A durable assessment has to accommodate both at once — the reported medical advance and the price existing shareholders pay for additional equity. The offering closed Friday. The filing has yet to be made.

Ad

Sellas Life Sciences Stock: New Analysis - 22 November

Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Sellas Life Sciences analysis...

Disclaimer...
en | US81642T2096 | SELLAS | boerse | 70544633 |